Centessa Pharmaceuticals plc (CNTA) Stock

About Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.

Centessa Pharmaceuticals plc is headquartered in GB.

Centessa Pharmaceuticals plc (CNTA) stock trades at $40.50 with a market capitalization of $6.27B. The stock is valued at a negative price-to-earnings (P/E) ratio of -22.75, reflecting a net loss over the last twelve months, price-to-book of 12.76, price-to-sales of 417.77. Over the past 52 weeks the stock has ranged between $12.78 and $40.56, and currently trades at or near its 52-week high.

On profitability, Centessa Pharmaceuticals plc generates a return on equity (ROE) of -60.37% (negative, reflecting a net loss), return on capital employed of -42.41%, an operating margin of -1386.67%, a net profit margin of -1320.00%.

Official website: www.centessa.com

Centessa Pharmaceuticals plc by the numbers, 2019–2025

Between 2019 and 2025 Centessa Pharmaceuticals plc reported revenue of $0 rising to $15.0M. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-198.0M.

The most recent net margin is -1320.00%. On a trailing twelve-month basis to Mar '26, revenue is $0 and net profit $-250.0M.

Borrowings stand at $8.0M, cash on hand is $276.6M, cash from operations was $-194.0M in the latest year, positive in 0 of the last 7.

Return on equity has averaged -60.4% over five years, and was -37.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Centessa Pharmaceuticals plc (CNTA) — frequently asked questions